Concord Biotech jumps 6% after USFDA approves Mycophenolate Mofetil ANDA

Concord Biotech received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.

Go to News Site